Mutations in exon 12 of the nucleophosmin (NPM1) gene (NPMc þ (NPM1 COOH terminal mutations)) define a distinct subset of acute myelogenous leukemias (AMLs), in which the NPMc þ protein localizes aberrantly to the leukemic cell cytoplasm. We have found that introduction of the most common NPMc þ variant into K562 and 32D cells sensitizes these cells to apoptosis induced by drugs such as bortezomib and arsenic trioxide (ATO) that induce reactive oxygen species (ROS) formation, and that cytotoxicity is prevented in the presence of N-acetyl-L-cysteine (NAC), an ROS scavenger. The substitution of tryptophan 288 (W288) by cysteine occurs in the great majority of NPM1c þ mutations. Mutagenesis of cysteine 288 to alanine re-localizes NPMc þ from the cytoplasm to the nucleolus and attenuates the sensitivity of cells expressing this mutation to bortezomib and ATO. Primary AML cells expressing NPMc þ are also significantly more sensitive than other AML cells to apoptosis induced by both drugs at pharmacologically achievable doses. We conclude that the presence of a cysteine moiety at position 288 results in the cytoplasmic localization of NPM1c þ and the increased sensitivity to bortezomib and ATO. These data suggest that bortezomib and ATO may have increased therapeutic efficacy in NPM1c þ leukemias.
INTRODUCTION
Nucleophosmin (NPM1) is a multifunctional phosphoprotein that resides predominantly in the nucleolus, but also shuttles to the nucleus and cytoplasm.
1 NPM1 is involved in diverse cellular functions, including ribosome biosynthesis, the processing and transport of ribosomal RNA and proteins, centrosome duplication, DNA repair and transcription, the regulation of the stability of tumor suppressors such as p53 and ARF, and as a chaperone for histones. 1 Mutations in exon 12 of the NPM1 gene are the most common genetic alterations in cytogenetically normal adult acute myelogenous leukemia (AML) patients, and are responsible for the aberrant cytoplasmic localization of NPM1 COOH terminal mutations (NPMc þ ). NPMc þ defines a distinct leukemia subset with a relatively favorable prognosis, [2] [3] [4] although an explanation for why individuals with this subset of acute leukemia respond to therapy more favorably is lacking.
A number of studies have provided evidence that the cytoplasmic localization of NPMc þ is due to the generation of additional nuclear export signal (NES) motifs at the C-terminus that occurs in conjunction with the loss of two tryptophan resides, W288 and W290, or of W290 alone in approximately one-third of adult AMLs. 5, 6 This conclusion is based on the introduction of a variety of site-directed mutants containing NES variants into cell lines, and is supported by the observation that the cytoplasmic accumulation of NPMc þ mutants is blocked by specific inhibitors of the nuclear export protein, Crm1/exportin-1. [5] [6] [7] In addition, reinsertion of tryptophan into the mutated protein at position 288 disrupts the NES site and restores nucleolar localization of the protein. 5 Bortezomib, a specific inhibitor of the 20S proteasome, has displayed clinical efficacy in a number of hematologic malignancies. [8] [9] [10] [11] [12] In addition to its direct inhibitory effects on the proteasome, 9 bortezomib has been noted to increase the level of intracellular reactive oxygen species (ROS) as an important component of its ability to induce apoptosis, [13] [14] [15] [16] [17] [18] autophagy [19] [20] [21] and differentiation. 22 A sustained increase in ROS generation appears, in turn, to enhance the inhibitory effects of bortezomib on proteasomal activity. 9 It has also been postulated that the bortezomib-induced increases in ROS levels in tumor cells may be the basis for its synergy with other chemotherapeutic agents. 9, 23 Arsenic trioxide (ATO) has emerged as the most active single agent in the treatment of acute promyelocytic leukemia, 24 and ATO-based therapies are being investigated in other cancers including other hematopoietic malignancies. [25] [26] [27] [28] [29] Although the mechanisms underlying ATO-induced cytotoxicity are not completely understood, ATO-mediated induction of ROS has been shown to reduce the membrane potential of mitochondria, enhance the release of cytochrome c and induce both caspasedependent and caspase-independent apoptosis. [30] [31] [32] AML has a poor prognosis in older patients, and intensive induction carries high morbidity and significant mortality. Thus, new therapies that more specifically target the molecular or metabolic abnormalities within leukemic cells have been highly sought. 28, 29 In this study, we show that the mutation of W288 to cysteine sensitizes cells to oxidative stress induced by both bortezomib and ATO. In addition, the specific acquisition of a cysteine residue at position 288 appears to be responsible for the cytoplasmic accumulation of the most common variants of NPMc þ that contain the W288C mutation. Thus, the mutation W288C may confer increased sensitivity to chemotherapeutic agents that generate increased levels of intracellular ROS, and could explain the more favorable prognosis of this molecular genetic marker.
MATERIALS AND METHODS

Cell culture and reagents
The U2OS osteosarcoma cell line and the K562 leukemia cell line were obtained from the American Type Culture Collection (Rockville, MD, USA). OCI/AML3 cells bearing exon-12 NPM mutation A 33 were kindly provided by Dr Kapil Bhalla from the University of Kansas Cancer Center. U2OS and K562 cells were grown at ambient oxygen concentration in DMEM supplemented with 10% FCS (HyClone, Thermo Scientific, Logan, UT, USA), 100 units/ml penicillin and streptomycin. The human AML cell line OCI-AML3 was grown in Alpha-MEM supplemented with 10% FBS, 1% nonessential amino acids, 1% sodium pyruvate, 100 units/ml penicillin and streptomycin. N-acetyl-L-cysteine (NAC), H 2 O 2 , doxycycline (Dox) and diamide were obtained from Sigma (St Louis, MO, USA). DAPI, 2 0 ,7 0 -dichlorofluorescein diacetate (H2-DCFDA) and dihydroethidium (DHE) were purchased from Molecular Probes, Inc. (Eugene, OR, USA). The following sources of antibodies were used: Goat anti-nucleostemin (NS) polyclonal antibody (AF 1638) from R&D Systems (Minneapolis, MN, USA); NPM1 monoclonal antibody (Ab10530) from Abcam (Abcam, Cambridge, MA, USA); mouse monoclonal anti-p53 (DO-1) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); rabbit polyclonal anti-NPM (#3542) from Cell Signaling Technology (Danvers, MA, USA); anti-actin monoclonal antibody from Sigma; mouse monoclonal Strep-TagII antibody from Novagen (Madison, WI, USA); anti-mutant nucleophosmin polyclonal antibody (PA1-46356) from Thermo Scientific (Rockford, IL, USA); rhodamine-conjugated goat anti-mouse secondary antibodies from Jackson ImmunoResearch (West Grove, PA, USA). The Annexin V apoptosis detection kit APC was obtained from eBioscience (San Diego, CA, USA). The retroviral vector pBMN-GFP (green fluorescent protein) and retroviral packaging cell line Phoenix Ampho or Eco were obtained from Orbigen (San Diego, CA, USA). Lenti-X Tet-On 3G Inducible Expression System was purchased from Clontech (Clontech Laboratories, Mountain View, CA USA).
Cell viability assay
In all, 50 000 K562 cells were plated per well in a 96-well plate, incubated with increasing concentrations of bortezomib for the times indicated, and proliferation measured with a Celltiter 96 Aqueous Non-radioactive Cell Proliferation Assay (Promega, Fitchburg, WI, USA). The expression of small interfering RNA (shRNA) was induced by 1 mg/ml Dox for 5 days, and the cells were incubated with increasing concentrations of bortezomib for the times indicated.
Mutagenesis and generation of NPM1 and its mutants with dual epitope tags Myc-tagged WT-NPM1 in pc-DNA3 was generously provided by Yanping Zhang from the University of North Carolina at Chapel Hill. Dual-tagged (Strep-TagII and Flag) NPM1 and its mutants were generated by two-step PCR amplification with high-fidelity Platinum pfx DNA polymerase (Invitrogen, Carlsbad, CA, USA). NPM1 isoform NPM1-259A and NPM1 mutants, including NPM1-C21A, NPM1-C104A, NPM1-C21 þ C104A, type A NPMc þ , C21 þ C104A-NPMc þ and cysteine 288 (C288A)-NPMc þ , were created using the Stratagene QuikChange mutagenesis kit (Stratagene, La Jolla, CA, USA). Primer sequences are listed in Supplementary Table 1 . The italicized bases represent restriction enzyme sites (BamH1 and Xho1) with four extra bases added at each end to promote efficient digestion. All constructs were confirmed by sequencing.
Construction of wt-NPM1 and NPM1 mutant retroviral plasmids and retroviral transduction of K562 cells NPM1, NPM1-259A, NPMc þ and the cysteine mutants of NPM1 and NPMc þ containing dual tags (Strep-TagII and Flag) in pcDNA3 were subcloned into the BamH1 and Xho1 Sites of the pBMN-IRES-GFP retroviral vector. To generate retrovirus, the Phoenix 293T Amphotropic retroviral packaging line was transfected with pBMN-GFP, pBMN-NPM1, pBMN-NPM1-259A, pBMN-NPMc þ or the cysteine mutants of NPM1 or NPMc þ constructs using lipofectamine (Invitrogen). At 12 h after transfection, the medium was replaced with fresh DMEM and cultured for an additional 24 h at 32 1C. The cell debris was removed by centrifugation at 500 g for 10 min, and the retrovirus-containing medium was collected. K562 (3 Â 10 5 cells/ml) and 32D cells (2 Â 10 5 cells/ml) were transduced with viral supernatants by spin inoculation at 2500 r.p.m. for 90 min at 30 1C in the presence of 2 mg/ml polybrene (Sigma Chemical, St Louis, MO, USA). For 32D cells, WEHI-3B conditioned medium was added to the infection medium immediately after spin inoculation to a final concentration of 20%. At 24 h post infection, virus-containing medium was replaced with fresh growth medium. At 72 h post infection, cells were sorted for high GFP expression using an FACSAria II sorter (BD Bioscience, Bedford, MA, USA). Sorted cells that stably expressed NPM1, NPMc þ and their cysteine mutants were collected and expanded.
Lentivirus production and transduction of K562 and 32D cells Strep-tag II and flag (SF)-tagged NPM1, NPMc þ and their cysteine mutants in the pBMN-IRES-GFP retroviral vector were subcloned into the BamH1 and Not1 sites of a Dox-inducible Lenti-viral expression vector pLVX-TRE3G from the Lenti-X Tet-On 3G Inducible Expression System (Clontech). The lentiviral supernatants of pLVX-TRE3G containing NPMs and regulator pLVX-Tet-3G were produced using a Lenti-X-HTX packaging system from Clontech. The pLVX-TRE3G vectors containing wt-NPM1, NPM1c þ and their cysteine mutants and the regulator vector LVX-Tet-3G were transfected into 293T cells using Xfect transfection reagent, the transfection medium was replaced with fresh DMEM after 24 h, and incubated for an additional 24-48 h. Cultures were passed through a 0.45-mM filter to remove cellular debris and to harvest the viral supernatants. K562 (3 Â 10 5 cells/ml) and 32D cells (2 Â 10 5 cells/ml) were co-transduced with pLVX-TRE3G and pLVX-Tet-3G viral supernatants at a ratio of 1:1 by spin inoculation with 2 mg/ml polybrene (2500 r.p.m. for 90 min at 30 1C). For 32D cells, WEHI-3B conditioned medium was added to the infection medium immediately after spin inoculation to obtain a final concentration of 20%. At 24 h post infection, virus-containing medium was replaced with fresh growth medium, followed by co-selection with G418 and puromycin after 72 h for 1 week. Cells were allowed to grow for at least another week without selection before performing an experiment. Dox-inducible expression was achieved by treating cells with 1 mg/ml Dox for 4-7 days.
Generation of lentiviral vectors for shRNAs and lentiviral transduction of K562 and OCI-AML3 cells
ShRNAs targeting NPM1 were purchased from Open Biosystems (Huntsville, AL, USA) (NPM1 shRNAs 7 and 8). The shRNA sequences used are shown in Supplementary Table 1. Lentiviral supernatants were prepared using 293T cells co-transfected with packaging plasmids pCMV-VSV-G and pCMVDR8.9 with Lipofectamine 2000 (Invitrogen) as previously described. 34 After an overnight incubation, the medium was replaced with fresh growth medium and at 48 h post transfection, virus-containing supernatants were collected by centrifugation at 500 g for 10 min at 4 1C and filtered through a 0.45-mm filter. K562, HL60 and OCI-AML3 cells were infected by spin inoculation (600 g, 90 min) in the presence of 2 mg/ml polybrene with lentiviral supernatants. At 48 h post infection, the lentiviralinfected cells were selected for stable infection with puromycin (2 mg/ml) for 7-10 days. Cells were allowed to grow for at least another week without selection before performing an experiment. Knockdown was confirmed by western blotting.
Cytospin and immunostaining
K562 and 32D cells were washed with phosphate-buffered saline (PBS) and cytospun onto coverslips at 500 r.p.m. for 5 min, fixed with 4% paraformaldehyde in PBS for 20 min at room temperature, and permeabilized with 0.1% Triton in PBS for 15 min at room temperature. Following blocking with 5% BSA in PBS, immunostaining of NS, NPM1 and NPMc þ was performed as described previously. 35 Flow cytometric analysis of apoptosis and ROS Apoptosis was determined using Annexin V-APC (eBioscience) according to the manufacturer's instruction. Cells were first incubated with APCconjugated Annexin V followed by DNA staining for 10 min at room temperature with 5 mM DAPI and flow cytometric analysis. Flow cytometric measurement of intracellular superoxide and hydrogen peroxide was performed as described previously. 35 NPMc þ sensitizes leukemic cells M Huang et al
Patient samples and apoptosis assays
Ficoll-purified flash frozen mononuclear cells from the bone marrow or peripheral blood of AML patients were obtained after informed consent according to institutional guidelines (Stanford University Institutional Review Board No. 6453). Cells were thawed in IMDM containing 20%FBS þ DNase and cultured for 4-6 h before sorting by flow cytometry. The blast gate was determined by CD33 þ /CD45 þ /SSC low profiling and cells were separated on an Aria II flow cytometer (BD Biosciences). AML blasts were plated in duplicate in EGM-2 medium (Lonza, Cologne, Germany) at a density of 1 Â 10 6 /ml in increasing half-log concentrations of bortezomib (0, 1, 3, 10, 30, 100, 300 and 1000 nM) or ATO (0, 0.1, 0.5, 1, 2, 5, 10 and 20 mM) for 24 h. Apoptotic cell death was analyzed by Annexin-Alexa647 staining followed by flow cytometric analysis.
Statistical analysis
Results are expressed as mean±s.d. The significance of differences between experimental conditions was examined using the Student's t-test. Differences with Po0.05 were considered as significant (* or #), and with P40.05 as not significant (n.s.). The significance of differences in the median IC50 of bortezomib and ATO between NPMc þ and non-NPMc þ primary AML patients was evaluated using the Mann-Whitney U-test for non-parametric distributions.
RESULTS
Sensitivity of cells expressing NPMc þ to bortezomib
To define the role of C-terminal NPM1 mutations in inducing selective drug sensitivity, constructs encoding NPM1-wt, the common NPMc þ mutant A, and NPM1-259A, an isoform lacking the C-terminal 35 amino acids, were stably expressed in the K562 human leukemia cell line. As shown in Figure 1a , SF-tagged wt-NPM1 and NPMc þ localize predominantly to the nucleolus and cytoplasm, respectively, while NPM1-259A is located primarily in the nucleus. Western blot analysis in Figure 1b shows that the mouse monoclonal antibody to NPM1 (m-NPM1) detects wt-NPM1 but not NPMc þ or NPM1-259A, whereas the rabbit polyclonal antibody (r-NPM1), generated using the N-terminal peptide of NPM1, recognizes all expressed forms of NPM1. The NPMc þ -specific antibody recognizes only NPMc þ (Figure 1b) . The use of these antibodies allows specific differentiation of the trafficking of wt-NPM1 as opposed to NPMc þ in subsequent studies.
Sorting of cells by GFP fluorescence resulted in a 90-99% pure population of relevant cells. GFP expression was stable for a minimum of 1 month after sorting. In contrast, the level of expression of SF-tagged NPMc þ was diminished over time, and was nearly undetectable 3 weeks after sorting. We therefore asked whether NPMc þ was subject to proteasomal degradation and used bortezomib to inhibit this pathway. K562 cells expressing NPMc þ were significantly more sensitive to bortezomib, as shown by loss of viability at 48 h (Figure 1c ) and the induction of apoptosis (Figure 1d; Supplementary Figure 1) as compared with K562 cells expressing wt-NPM1, NPM1-259A or GFP vector alone. However, bortezomib treatment did not increase the overall level of expression of NPMc þ .
Association of ROS generation with bortezomib-induced apoptosis Recent studies have established that ROS has an important role in bortezomib-induced cytotoxicity in a variety of tumor cells. 9 We therefore asked whether bortezomib induces ROS in K562 and OCI-AML3 cells, and whether ROS activation is related to bortezomib-induced apoptosis. As shown in Figure 2a , bortezomib treatment stimulated an increase in the superoxide-specific DHE-derived fluorescence 36 ( Figure 2a ), but not in the hydrogen peroxide dye DCFDA-H2 derived fluorescence 36 (Figure 2b ), indicating that bortezomib increases the production of superoxide but not of hydrogen peroxide in these cells. Pre-treatment with the antioxidant NAC prevented the generation of superoxide (Figures 2c and d) , and attenuated bortezomib-induced apoptosis in OCI-AML3 (Figure 2e ) and K562 (Figure 2f ) cells.
Induced silencing of NPM1 attenuates bortezomib-and ATOinduced apoptosis To determine whether NPMc þ expression accounted for the difference in bortezomib-induced cytotoxicity, we reduced NPM1 and NPMc þ expression using Dox-inducible lentiviral shRNAs targeting NPM1. As shown in Figure 3a and Supplementary  Figure 2A , NPM1-shRNAs 7 and 8 decreased the expression of both wt-NPM1 and NPMc þ , whereas the expression of HSP70 and actin was unchanged. Depletion of NPMc þ through expression of NPM1 shRNAs markedly reduced the extent of bortezomib-induced apoptosis in OCI-AML3 cells that express endogenous NPMc þ (Figures 3b and c) , and attenuated bortezomib-induced cytotoxicity in K562 cells expressing NPMc þ (Supplementary Figure 2B) . Of note, neither apoptotic cell death (Figure 4a ) nor growth inhibition (Supplementary Figure 2C) resulted from the expression of NPM1 shRNAs in either OCI-AML3 cells (wt-p53; Figure 3a ) or K562 cells (p53 null; Supplementary Figure 2A) ; however, a slight increase in the level of CD11b was observed in OCI-AML3 cells, indicating a small increment in differentiation (Figure 4) .
To confirm that NPMc þ expression mediates sensitization of AML cells to apoptosis through an ROS-dependent mechanism, cells were also exposed to the pro-oxidant, ATO. 30, 31 ATO also induced a dose-dependent increase in apoptotic cell death that was significantly attenuated by depleting NPM and NPMc þ through the expression of NPM1-shRNAs (Figures 4c and d) . 
Role of C288 in the cytoplasmic localization of NPMc þ
In examining the spectrum of NPMc þ mutations in relation to the increase in ROS generation, we noted that W288 is mutated to C288 in 495% of NPMc þ mutations that have been documented in AML patients. 2, [37] [38] [39] [40] The frequency of various NPMc þ variants is reviewed in Figure 5a . To determine whether C288 is essential for the cytoplasmic localization of NPMc þ , C288 and two other cysteines (C21 and C104) that are located in the N-terminal oligomerization domain of NPMc þ were independently mutated to alanine. SF-tagged wt-NPM1, NPMc þ and the corresponding C-4A mutants were introduced into K562 cells using an inducible lentiviral TRE-3G expression system. Strikingly, the C288A-NPMc þ mutant localized almost entirely to the nucleolus, as shown by costaining with the nucleolar protein NS antibody (Figure 5b) . However, substitution of alanine for the two N-terminal cysteine residues (C21 and C104) did not alter the cytoplasmic localization of NPMc þ (Figure 5b ). Of note, substitution of either C21 or C104 partially suppressed the ability of wt-NPM1 to form pentamers, and mutation of both cysteine residues markedly diminished pentamer formation in both K562 (Figure 5c ) and U2OS cells (Supplementary Figure 3) . In contrast, the C288A-NPMc þ substitution did not reduce oligomerization (Figure 5c ). The expression level of each ectopically expressed NPM in relation to endogenous NPM1 is also shown in Figure 5c , demonstrating a relatively constant ratio of expressed to endogenous protein.
Role of C288 in sensitivity to bortezomib and ATO Due to the potentially confounding variables in the K562 cell line resulting from activation of the BCR-ABL oncogenic signaling pathway, 41 we established a non-leukemic myeloid 32D cell model to further investigate the role of NPMc þ and its cysteine variants in sensitizing non-leukemic myeloid cells to bortezomibinduced apoptosis. SF-tagged wt-NPM1, NPMc þ and their cysteine mutants were inducibly expressed in 32D cells with Dox using the TRE-3G lentiviral expression system. The levels of expressed SF-tagged NPM1 and mutants were determined before and after Dox induction (Figure 6a) . Consistent with the results obtained in K562 cells, overexpression of NPMc þ and C21 þ C104A-NPMc þ increased sensitivity to bortezomibinduced apoptosis, whereas C288A-NPMc þ did not (Figures 6b  and c) . Moreover, the potentiating effects of NPMc þ on bortezomib-induced apoptosis were prevented to a large extent by pre-incubation with 10 mM NAC (Figure 6d) . Similar results were obtained in K562 cells expressing NPMc þ and its cysteine variants (data not shown). Figure 5B) . NAC treatment also attenuated ATO-induced apoptosis (Figure 7b; Supplementary Figure 4B) . These results suggest that ATO-induced apoptosis results from the generation of superoxide, as has been shown previously. 42 ATO also induced a dose-dependent increase in apoptosis in 32D cells expressing inducible NPMc þ and NPMc þ C21 þ 104A, but not in cells expressing wt-NPM1 or NPMc þ C-288A (Figure 7c ; Supplementary Figure 4C ).
Induction of apoptosis by bortezomib and ATO in primary AML blasts To determine whether the expression of NPMc þ in primary AML cells also sensitizes to bortezomib and ATO, we sorted AML blasts into a CD33 þ /CD45 þ /SSC low population. Viability after sorting and short-term cultures ranged from 70 to 90%. The FAB classification, cytogenetic information and clinical characteristics of 10 AML patients are shown in Supplementary Figure 6A . We then determined the IC50s of both drugs for the induction of apoptotic cell death. As shown in Figure 8 , AML cells containing the NPM1c þ mutation A were significantly more sensitive to ATO-induced apoptosis than four other non-NPMc þ AML cells with a median IC50 of 6.1 versus 2.3 mM (*Po0.05), respectively.
In addition, four of the five NPMc þ cells showed increased sensitivity to bortezomib-induced apoptosis as compared with five non-NPMc þ AML cells (median IC50 3.2 versus 7.9 nM for non-NPMc þ , *Po0.05). The presence of an FLT3 mutation in two samples (AML1 and AML2) did not appear to alter sensitivity to bortezomib or ATO in NPMc þ patients (Supplementary Figures 6A and B) .
DISCUSSION
Identification of C288 as a redox-sensitizing moiety Nuclear-cytoplasmic trafficking of proteins is regulated by a number of nuclear import and export factors. [43] [44] [45] [46] Several studies have provided evidence that a new leucine-rich NES created by the NPMc þ mutation promotes CRM1-dependent nuclear export of NPMc þ , thus resulting in accumulation of NPMc þ in the cytoplasm. [5] [6] [7] 47, 48 In the current study, we demonstrate that the redox-sensitive C288 generated by the NPMc þ mutation has an important role in regulating the cytoplasmic accumulation of NPMc þ . Mutation of C288 to alanine enables NPMc þ to remain in the nucleolus, suggesting that this cysteine residue may be sufficient to cause cytoplasmic localization independent of the loss of W288 and the acquisition of additional leucine-rich nuclear export motifs resulting from the C-terminal extension. [5] [6] [7] The observation, that C21A and C104A mutations disrupt the oligomerization of NPMc þ but do not alter its cytoplasmic localization, suggests that these two cysteines do not participate in the redox-mediated changes in localization and that localization is independent of the oligomerization status of NPMc þ . Our results are consistent with the recent finding that fusion proteins containing the most common NPM COOH-terminal LxxxVxxVxL export signals that are present in the majority of NPMc þ mutations are not exported into the cytoplasm. These data support the view that the leucine or valine substitutions into this NES motif result in intrinsically weak nuclear export activity. 6 They are also in line with a recent finding that reinsertion of W288 alone into type A NPMc þ mutants relocates the NPMc þ variant to the nucleolus. 5 The result showing that the C288A substitution alone is sufficient to prevent cytoplasmic export of the type A NPMc þ mutant suggests that this mutation overrides the effects of the loss of two tryptophans and the gain of the leucine-rich NES. As the Cys288 mutation is present in 97.8% of reported NPMc þ mutations (Figure 6a) , we suggest that the acquisition of cysteine at this site is central to the cytoplasmic localization of these mutants. Of note, a few rare NPMc þ variants including NPM mutation E retain W288 (Figure 6a ). The nuclear export of these mutants may be due to the concomitant presence of an LxxxL/M/ FxxVxL NES motif, as this motif appears to constitute a stronger NES than does the LxxxVxxVxL motif present in the most common C288-containing NPM1 variants. 6 The precise structural basis for the cytoplasmic localization resulting from Cys288 remains to be defined. Analysis of the C-terminal structure of NPM1 using nuclear magnetic resonance has shown that the two conserved tryptophans, W288 and W290, are incorporated into the hydrophobic core of a well-defined triple helix domain. 49 NPMc þ mutations resulted in a loss of this tertiary structure and unfolding of the C-terminus. 49 We postulate that disruption of the tertiary structure at the C-terminus may enhance the susceptibility of the thiol moiety ( À SH) of C288 to oxidative modification and enhance the interaction between the NPMc þ NES and CRM1, resulting in increased export of NPMc þ to the cytoplasm in response to ROS generation.
Significance of C288 in bortezomib-and ATO-induced apoptosis of NPMc þ expressing cells An important clinical application of the association between cellular redox status and the level of NPMc þ in the cytoplasm is the finding that NPMc þ expression renders non-malignant or leukemic myeloid cells more sensitive to apoptosis induced by bortezomib and ATO. The ability of the superoxide scavenger NAC to protect cells from both bortezomib-and ATO-induced apoptosis strongly supports a causal relationship between the increase in superoxide generated by both drugs and apoptosis. More direct evidence for the role of C288 is provided by the demonstration that enhanced bortezomib or ATO sensitivity is lost in cells that express the C288A mutant, but not in cells expressing NPM containing the C21A and C104A mutations.
The induction of apoptosis by both drugs is associated with an increase in superoxide (O 2 À ) generation. It has been proposed that bortezomib may induce superoxide by altering the oxidationreduction pathways, interfering with the mitochondrial electron transport system and/or by inducing endoplasmic reticulum stress due to the accumulation of polyubiquitinated proteins. 50, 51 ATO-induced superoxide generation depends on concomitant downregulation of antioxidant enzymes 30, 52 and upregulation of oxidases. 32, [53] [54] [55] The mechanisms through which NPMc þ mediates increased response to bortezomib-or ATO-induced ROS remain to be fully evaluated. NPMc þ expression may disrupt the balance between ROS-generating and ROS-detoxification systems.
In addition to their effects on ROS induction in NPMc þ cells, each of these drugs has additional mechanisms of action that may contribute to their toxicity, although the significant reversal of toxicity with NAC indicates that these effects may have a more secondary role in ROS induction.
In an early clinical trial study, Munshi et al. 25 reported that ATO as a single agent was not effective in a phase II study of 11 relapsed/refractory or de novo AML and non-acute promyelocytic leukemia patients. However, only two of these patients had a normal karyotype, and the NPM1 status was not reported. 25 In a recent clinical trial of ATO alone, one of the seven AML patients of unknown genetic phenotype who were resistant to therapy obtained a complete remission and one a partial remission. 56 In two other clinical studies, the addition of ATO to low-or high-dose cytarabine and idarubicin appeared to improve the complete remission rate, although again NPM1 mutational status was not determined. 28, 57 In our present study, NPMc þ AML leukemic cells from five AML patients were significantly more sensitive to ATO-or bortezomib-induced apoptosis than the other non-NPMc þ AML leukemic cells. This sensitivity was not altered by the co-existence of the FLT3 mutation in the two cases (Supplementary Figure 6A and B) . Special culture conditions and cell sorting were used to ensure a homogeneous population of leukemic cells with high viability that was retained in control cells during the 24 h of incubation. Although the sample size is small, these data support the results obtained with cultured cell lines for both drugs. Given the current paucity of clinical data, a clinical trial of ATO and/or bortezomib, a new generation proteasome inhibitor, in relapsed or refractory NPM1c þ AML seems to be warranted.
In summary, we propose a previously unrecognized mechanism for the cytoplasmic accumulation of NPMc þ variants containing C288. In addition, the acquisition of this single amino acid sensitizes NPMc þ expressing cells to agents such as bortezomib and ATO that induce oxidative stress. The association between bortezomib-and ATO-mediated induction of superoxide and apoptosis also raises the possibility that superoxide generation could be used as a biomarker to predict the therapeutic efficacy and clinical response of patients who have these mutations to pro-oxidant drugs.
